NCT06633835View on ClinicalTrials.gov

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

660

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

August 31, 2025

Conditions
COVID-19Vaccine-Preventable DiseasesSARS CoV 2 Infection
Interventions
BIOLOGICAL

protein subunit: Novavax COVID-19 vaccine

Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.

BIOLOGICAL

Pfizer mRNA COVID-19 vaccine

Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.

Trial Locations (1)

84108

University of Utah School of Medicine, Salt Lake City

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
collaborator

University of Utah

OTHER

lead

Novavax

INDUSTRY

NCT06633835 - Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States | Biotech Hunter | Biotech Hunter